MGX - Metagenomi, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
2.91 0.13 (4.64%)	---	---	-0.08 (-2.41%)	0.07 (2.41%)	0.06 (1.95%)	-0.09 (-2.72%)	-0.09 (-2.72%)

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.54
Diluted EPS:: -0.54
Basic P/E:: -5.6387
Diluted P/E:: -5.6387
RSI(14) 1m:: 39.97
VWAP:: 3.04
RVol:: 0.634

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	3.14 +0.04 (+1.26%)	Oct 15 15:59
1m	Price increase 1m	3.11 +0.04 (+1.25%)	Oct 15 15:18
1m	Price increase 1m	3.01 +0.03 (+1.18%)	Oct 15 13:03
1m	Price decrease 1m	2.96 -0.03 (-1.0%)	Oct 15 11:26
1m	Price decrease 1m	2.99 -0.04 (-1.29%)	Oct 15 10:25